NetworkNewsBreaks – Nemaura Medical Inc.’s (NA
Post# of 73
(Total Views: 158)
Posted On: 04/01/2022 3:31:52 PM
NetworkNewsBreaks – Nemaura Medical Inc.’s (NASDAQ: NMRD) Technologies Stand Distinct
Nemaura Medical (NASDAQ: NMRD) recently launched its MiBoKo metabolic health and wellness program, offering a distinct competitive advantage with AI-powered monitoring devices that are non-invasive, easy to wear and cost-effective. “Sensors developed by Nemaura stand apart from competitor devices that employ microneedles coated with enzymes and polymers — some of which require insertion for up to five days. Besides causing discomfort upon insertion, users report trauma and bruising in addition to changes to the skin surface. In contrast, Nemaura Medical’s sugarBEAT(R) and proBEAT(TM) continuous glucose monitors (“CGMs”) sit on the surface of the skin, are easy to apply, and can be worn comfortably without the need for extended periods of wear, providing real-time insights into a person’s state of metabolic health, dietary guidance and exercise recommendations with the aim of improved long-term health and wellness,” a recent article reads. “At Nemaura, we continue to look for the intersection of patient comfort and convenience through advanced and unique technology that addresses significant health care needs for large patient populations,” said Nemaura CEO Dr. Faz Chowdhury. “We believe that MiBoKo offers insights into metabolic health in a user-friendly way unlike any other program on the market.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Nemaura Medical (NASDAQ: NMRD) recently launched its MiBoKo metabolic health and wellness program, offering a distinct competitive advantage with AI-powered monitoring devices that are non-invasive, easy to wear and cost-effective. “Sensors developed by Nemaura stand apart from competitor devices that employ microneedles coated with enzymes and polymers — some of which require insertion for up to five days. Besides causing discomfort upon insertion, users report trauma and bruising in addition to changes to the skin surface. In contrast, Nemaura Medical’s sugarBEAT(R) and proBEAT(TM) continuous glucose monitors (“CGMs”) sit on the surface of the skin, are easy to apply, and can be worn comfortably without the need for extended periods of wear, providing real-time insights into a person’s state of metabolic health, dietary guidance and exercise recommendations with the aim of improved long-term health and wellness,” a recent article reads. “At Nemaura, we continue to look for the intersection of patient comfort and convenience through advanced and unique technology that addresses significant health care needs for large patient populations,” said Nemaura CEO Dr. Faz Chowdhury. “We believe that MiBoKo offers insights into metabolic health in a user-friendly way unlike any other program on the market.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Nemaura Medical Inc. (NMRD) Stock Research Links
Scroll down for more posts ▼